<DOC>
	<DOCNO>NCT00944801</DOCNO>
	<brief_summary>Glioblastomas represent 40 % tumor central nervous system ( CNS ) among lethal tumor . Temozolomide ( TMZ ) combine radiotherapy first substance significantly improve overall survival ( 14.6 month ) compare surgery radiotherapy alone increased proportion patient survive 2 year 26 % . TMZ show best efficacy patient methylated O6-methylguanine-DNA methyltransferase ( MGMT ) promoter part eliminate stem cell-like tumor cell . Among patient methylated MGMT promoter , median survival treatment combine radio-chemotherapy 21.7 month , compare 15.3 month among assigned radiotherapy . In absence methylation MGMT promoter , small statistically insignificant difference survival treatment group . Doxorubicin one effective substance vitro cell derive glioblastoma . However , significant effect vivo due poor blood-brain-barrier penetration . In tumor model , tissue CSF-concentrations doxorubicin substantially increase sterically stabilize liposome use result comparable clinical response use approximately half dose stabilize liposome compare conventional doxorubicin . A pegylated formulation ( PEG-liposomal Doxorubicin ) even improve penetration blood-brain barrier . Case series two phase II-studies patient recurrent glioblastoma show modestly promising result PEG-Dox . In study , investigator treat patient recurrent glioblastoma 20 mg/m2 PEG-Dox day 1 15 28-day cycle . To determine dose limit toxicity PEG-Dox combine prolonged administration TMZ , investigator perform phase I part ahead phase II study . To investigate , mean historical control analysis , addition PEG-Dox TMZ radiotherapy improve survival patient , investigator choose similar inclusion criterion identical TMZ radiotherapeutic regime EORTC26981/NCIC-CE.3 study .</brief_summary>
	<brief_title>Pegylated Liposomal Doxorubicine Prolonged Temozolomide Addition Radiotherapy Newly Diagnosed Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>newly diagnose glioblastoma centrally confirm histology Karnofsky performance score ( KPS ) &gt; 70 % stable corticosteroid within 2 week inclusion leucocytes &gt; 3/ul , thrombocytes &gt; 100/ul , Hb &gt; 10 g/dl additional standard criterion tumor history pretreatment radiotherapy brain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>glioblastoma</keyword>
	<keyword>first-line</keyword>
	<keyword>clinical trial</keyword>
	<keyword>PEG-liposomal doxorubicin</keyword>
	<keyword>temozolomide</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>phase 1</keyword>
	<keyword>phase 2</keyword>
</DOC>